Author

A. Tan

Observed name: Alan Tan

Institution: Rush University Medical Center

Observed institutions: Cedars-Sinai Medical Center, Rush University Medical Center, Weill Cornell Medicine

OpenAlex ID: A5042042013

LBA63 PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)

2022 · R. Aggarwal, G. Heller, et al. · Annals of Oncology · 5

The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent “BCG-exposed” high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).

2026 · Eugene J. Pietzak, Karla V. Ballman, et al. · Journal of Clinical Oncology · 1

2433P Preliminary safety and clinical activity from a phase II study of apalutamide + carotuximab in advanced, castration-resistant prostate cancer

2025 · E.M. Posadas, U. Swami, et al. · Annals of Oncology

635 Reprogramming the tumor microenvironment by a second-generation recombinant modified vaccinia virus Ankara

2022 · S. Liu, G. Mazo, et al. · Journal of Investigative Dermatology

Works count: 4

Citation count: 6

H-index: 1

I10-index: